Network connectivity determines cortical thinning in early Parkinson's disease progression
Yau, Y.; Zeighami, Y.; Baker, T. E.; Larcher, K.; Vainik, U.; Dadar, M.; Fonov, V. S.; Hagmann, P.; Griffa, A.; Mišić, B.; Collins, D. L.; Dagher, A.
(2018) Nature Communications, volume 9, issue 1
(Article)
Abstract
Here we test the hypothesis that the neurodegenerative process in Parkinson's disease (PD) moves stereotypically along neural networks, possibly reflecting the spread of toxic alpha-synuclein molecules. PD patients (n = 105) and matched controls (n = 57) underwent T1-MRI at entry and 1 year later as part of the Parkinson's
... read more
Progression Markers Initiative. Over this period, PD patients demonstrate significantly greater cortical thinning than controls in parts of the left occipital and bilateral frontal lobes and right somatomotor-sensory cortex. Cortical thinning is correlated to connectivity (measured functionally or structurally) to a "disease reservoir" evaluated by MRI at baseline. The atrophy pattern in the ventral frontal lobes resembles one described in certain cases of Alzheimer's disease. Our findings suggest that disease propagation to the cortex in PD follows neuronal connectivity and that disease spread to the cortex may herald the onset of cognitive impairment.
show less
Download/Full Text
Keywords: General Chemistry, General Biochemistry,Genetics and Molecular Biology, General Physics and Astronomy
ISSN: 2041-1723
Publisher: Nature Publishing Group
Note: Funding Information: PPMI-a public-private partnership-is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, Teva, and UCB. This research was supported by grants from the Michael J. Fox Foundation for Parkinson's Research, the W. Garfield Weston Foundation, and the Alzheimer's Association; the Canadian Institutes of Health Research; and the Natural Sciences and Engineering Research Council of Canada to A.D. Y.Y. is a Vanier Scholar and receives funding from the Canadian Institute of Health Research. Y.Z. holds the Jeanne Timmins Costello Fellowship. Funding Information: PPMI—a public–private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, Teva, and UCB. This research was supported by grants from the Michael J. Fox Foundation for Parkinson’s Research, the W. Garfield Weston Foundation, and the Alzheimer’s Association; the Canadian Institutes of Health Research; and the Natural Sciences and Engineering Research Council of Canada to A.D. Y.Y. is a Vanier Scholar and receives funding from the Canadian Institute of Health Research. Y.Z. holds the Jeanne Timmins Costello Fellowship. Publisher Copyright: © 2017 The Author(s).
(Peer reviewed)